Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
Status:
Completed
Trial end date:
2019-07-25
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy
of extended-release naltrexone plus bupropion as a combination pharmacotherapy for
methamphetamine use disorder. Participants will be randomly assigned to the active medication
combination (AMC) group or matching placebo group and will receive medications over the
course of 12 weeks. Follow-ups will occur in weeks 13 and 16.
Phase:
Phase 3
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
National Institute on Drug Abuse (NIDA) The Emmes Company, LLC The EMMES Corporation